Charles Explorer logo
🇨🇿

Myocardial fibrosis detected by magnetic resonance in systemic sclerosis patients - Relationship with biochemical and echocardiography parameters

Publikace na Lékařská fakulta v Plzni |
2017

Tento text není v aktuálním jazyce dostupný. Zobrazuje se verze "en".Abstrakt

Objectives: Systemic scleroderma (SSc) is a rare connective tissue disease presenting with fibrosis affecting skin and internal organs. Cardiovascular magnetic resonance (CMR) with quantification of extracellular volume (ECV) and T1 mapping might help to detect heart involvement.

We aimed to evaluate whether myocardial involvement correlates with functional and laboratory parameters. Methods: Thirty-three asymptomatic SSc patients (29 women, aged 56.6 +/- 12.2 years) and 20 controls (10 women, 53.7 +/- 13.1 years) were examined using CMR, echocardiography, functional pulmonary test and laboratory assessment.

Results: SSc patients had higher ECV (27.5 +/- 2.8 vs. 22.8 +/- 1.9%, P < 0.0001) and native T1 values (1258.9 +/- 51.2 vs. 1192.2 +/- 32.6, P < 0.0001) compared to controls. Plasma level of growth differentiation factor 15 (GDF-15) and galectin-3 correlated with ECV (r = 0.35; P = 0.0076 and r = 0.38; P = 0.0081) and native T1 (r = 0.31; P = 0.023 and r = 0.35; P = 0.012).

GDF-15 was also negatively correlated with diffusing capacity of the lung for carbon monoxide (r = -0.58; P = 0.0004) and positively correlated with modified Rodnan skin score (r = 0.59; P = 0.0003). Conventional echocardiography parameters were similar in SSc patients and controls.

However, the global longitudinal peak systolic strain (GLPS) was lower in SSc patients compared to controls (18.6 +/- 1.6 vs. 21.1 +/- 1.2%; P < 0.0001). GLPS also negatively correlated with native T1 (r = -0.35; P = 0.0097), ECV (r = -0.33; P = 0.014), GDF 15 (r = -0.31; P = 0.022), and galectin-3 (r = -0.37; P = 0.0076).

Conclusions: Asymptomatic heart involvement is common in SSc patients and includes focal and diffusemyocardial fibrosis. GDF-15 and galectin-3 were positively correlated with myocardial fibrosis parameters.

Future outcome studies must show whether measurement of GDF-15 and galectin-3 in SSC patients might be may be useful in clinical practice.